The trial involves newborns who are full-term, meaning they are born at or after 37 weeks of pregnancy.

The newborn must be in a state where resuscitation is necessary, specifically if they are experiencing circulatory arrest or a very slow heart rate (less than 60 beats per minute).

The decision to resuscitate the newborn is made according to the guidelines of the European Resuscitation Council 2021.

Initial steps of cardiopulmonary resuscitation are performed, including establishing effective breathing for the newborn.

If these steps do not restore normal heart function, an injection of adrenaline is indicated.

The medication used is ADRENALINE AGUETTANT 1 mg/ml, which is a solution for injection.

The adrenaline is administered intravenously, meaning it is injected directly into a vein.

The goal is to achieve a successful resuscitation within 90 seconds using the VOW procedure, which involves umbilical vein catheterization through Wharton’s jelly.

The time taken to place the umbilical route and start the adrenaline injection is recorded.

The time from the start of the procedure to achieving a heart rate greater than 100 beats per minute is measured.

The frequency of any failures during the procedure is documented, including reasons such as time exceeded or ineffective injection.

The newborn is monitored for any adverse events in the 72 hours following the injection.

The mortality rate is assessed at one hour and at hospital discharge or 28 days, whichever comes first.

The trial aims to model the relationship between the success of the procedure and factors such as the condition of the umbilical cord or the experience of the healthcare provider.